Dexcom (NSDQ:DXCM) topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results.
The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year.
For the full year of 2018, Dexcom is slated to post sales of $1.03 billion, up 42% from 2017.
Analysts on Wall Street estimated that the company would record fourth-quarter sales of $284.7 million.
“We are thrilled with Dexcom’s full-year performance in 2018, with growth exceeding our original expectations by a significant margin and driving us to a historic milestone of more than $1 billion in annual revenues,” chairman, president & CEO Kevin Sayer said in prepared remarks.
“Our success in 2018 was driven by increasing awareness of the importance of CGM in managing diabetes, supported by the approval and launch of Dexcom’s G6 CGM platform both in the U.S. and internationally,” Sayer added.
The glucose monitor developer noted that it expects to post full-year revenue for 2019 between $1.175 billion and $1.225 billion.
DXCM shares were trading at $127.28 apiece in morning activity today, up 9.5%.
Intersect ENT shares hold steady after Q4 prelims
Intersect ENT (NSDQ:XENT) said today that it expects to record fourth-quarter sales of $32.6 million – $32.8 million, up 11% from the same period last year. The company is slated to post FY18 sales of $108.3 million – $108.5 million, up from $96.3 million in 2017.
Analysts on Wall Street estimated that Intersect ENT will post Q4 sales of $32.2 million on full-year sales of $107.9 million.
For 2019, Intersect ENT forecasted a full-year revenue range of $123 million – $127 million.
XENT shares were trading at $26.83 apiece in morning activity today, down -0.2%.
Q4, FY18 prelims send TransEnterix shares up
TransEnterix (NYSE:TRXC) reported today that it expects to record fourth-quarter revenue of $7.4 million and full-year sales of $24 million, topping estimates on Wall Street.
The company also touted that in 2018 it sold 15 of its Senhance surgical systems.
“2018 was a significant year for TransEnterix as we continued to drive the global commercial adoption of the Senhance System and made great strides towards expanding the applicability of the system to a greater number of surgeons and hospitals across the globe,” president & CEO Todd Pope said in prepared remarks.
“We view 2019 as an opportunity to leverage the tremendous progress we made in 2018 and bring the benefits of Senhance Surgery to more patients, surgeons and hospitals both in the U.S and internationally,” he added.
Analysts expected TransEnterix to report Q4 sales of $7.35 million and FY18 revenues of $23.89 million. TRXC shares were trading at $2.57 apiece in morning activity today, up 7.7%.
Apyx Medical shares jump on Q4, FY18 prelims
Shares in Apyx Medical (NSDQ:APYX) rose this morning after the medical device maker, formerly Bovie Medical, posted its preliminary fourth-quarter and full-year financial results.
For the fourth quarter ended Dec. 31, Apyx Medical expects to post revenues of $5.9 million – $6.1 million, up 61% – 67% compared to the same period last year. The company is slated to post full-year revenues for 2018 of $16.7 million – $16.9 million, up 63% – 65% from 2017.
“Our fourth quarter revenue results exceeded the high-end of our guidance range and reflects the continued success we are having in commercializing our J-Plasma technology under the RenuvionTM brand in the cosmetic surgery market,” president & CEO Charlie Goodwin said in prepared remarks. “Our strategic focus has resulted in Advanced Energy sales growth of more than 72% in 2018 and we are experiencing a growing awareness of our differentiated technology in the U.S. cosmetic surgery market as more and more clinicians appreciate Renuvion’s unique ability to manage heat which allows for improved tissue effect and treatment time.
The outlook for 2019 is very positive for Apyx Medical; we are investing in our selling infrastructure to maximize the opportunity to gain share in the U.S. cosmetic surgery market with our disruptive technology, and we achieved another milestone near the end of the fourth quarter with the announcement of a 510(k) submission requesting clearance for a new clinical indication to market and sell our Renuvion Cosmetic Technology for dermal resurfacing procedures. We have a strong balance sheet and a focused plan to encourage broad-based adoption of Renuvion, which we believe ultimately achieves strong, sustained and profitable growth for the benefit of our stockholders,” he added.
APYX shares were trading at $7.56 apiece in morning activity, up 14.2%.
